Drug intelligence / Profile preview

KDF2001

Development stage: Preclinical
Lead developer: Kyungdong Pharmaceutical
Modality: Small Molecules

Overview

KDF2001 is a small molecule drug candidate being developed by Kyung Dong Pharma as an Incrementally Modified Drug (IMD) for the treatment of diabetes. In the South Korean regulatory framework, an IMD is a drug that has been modified in its composition, dosage form, or indication from a previously approved drug to provide a clinical improvement, such as enhanced efficacy, safety, or patient compliance. KDF2001 was listed in the company's pipeline as being in the preclinical stage of development as of early 2021. The specific active ingredient and molecular target have not been publicly disclosed.

Beyond the preview

Go deeper on KDF2001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KDF2001.

Explore the full profile